Literature DB >> 28253726

Morbidity, mortality and long term survival in patients with vascular resection in pancreatic cancer - single center experience.

D Pindak, M Tomas, J Dolnik, R Duchon, J Pavlendova.   

Abstract

Although venous resection in pancreatic cancer is widely used method, recently published data about its safety and survival benefit showed conflicting results. A retrospective case matched study was performed to compare the results of patients who underwent venous resection to those with no venous resection during radical surgery in pancreatic cancer.From January 2010 to December 2015, 297 pancreatic resections due to pancreatic tumor were performed in the National Cancer Institute (NCI). Fifty-three patients with venous resection were identified and enrolled into the study and matched with 66 patients without vascular resection during radical resection of pancreatic head/body cancer. Both groups matched for age, ASA score, need for preoperative biliary drainage and clinical staging of the tumor. Morbidity was determined according Clavien and Dindo classification [1] and was similar in both groups of patients (p = 0.48). Thirty day postoperative mortality was also equal in both groups 5.6 vs 4.5% (p > 0.99) and long term survival was with no significant difference. Median overall survival was 18.8 vs 20.7 months (p = 0.33) for patients with/without venous resection.Therefore we consider venous resection in pancreatic cancer safe procedure with equal morbidity and perioperative mortality as in patients with no need for vascular resection and with the same long term survival if R0 resection is achieved.

Entities:  

Keywords:  morbidity mortality.; neoplasm; pancreas

Mesh:

Year:  2017        PMID: 28253726     DOI: 10.4149/neo_2017_318

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  4 in total

1.  Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.

Authors:  Lei Huang; Yesilda Balavarca; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Vesna Zadnik; Maja Primic-Žakelj; Margit Mägi; Robert Grützmann; Marc G Besselink; Petra Schrotz-King; Hermann Brenner; Lina Jansen
Journal:  BMC Med       Date:  2019-03-25       Impact factor: 8.775

2.  Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations.

Authors:  Ge Li; Cheng-Yu Liao; Jiang-Zhi Chen; Long Huang; Can Yang; Yi-Feng Tian; Yi-Ting Wang; Qiang Du; Qian Zhan; Yan-Ling Chen; Shi Chen
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

3.  Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Ge Li; Jiang-Zhi Chen; Shi Chen; Sheng-Zhe Lin; Wei Pan; Ze-Wu Meng; Xin-Ran Cai; Yan-Ling Chen
Journal:  Cancer Med       Date:  2020-03-17       Impact factor: 4.452

4.  Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.

Authors:  Long Pan; Jing Fang; Chenhao Tong; Mingyu Chen; Bin Zhang; Sarun Juengpanich; Yifan Wang; Xiujun Cai
Journal:  World J Surg Oncol       Date:  2019-12-31       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.